



GARNETT McKEEN LABORATORY, INC.

Poly-MVA for Fatigue and Mitochondrial Support

- ❖ **Poly-MVA is a novel supplement which demonstrates an enhanced redox capacity. This means it is extremely efficient at accepting and transferring energy (electrons). Publications and clinical observations have demonstrated its ability to provide cellular energy to alleviate fatigue and attenuate metabolic consequences of aging or disease.**

Scientific Studies:

With age there is a decrease in the number of mitochondria (the power house of the cell) and their efficiency. Studies examined aged heart and brain and found that Poly MVA administration (human equivalent dose between ½ and 2 tsp/day) increased aerobic metabolism (an average increase in Krebs Cycle enzymes of 225%; and 150% increase in electron transport chain enzymatic activity). In addition, there was a statistically significant reduction in oxidative stress to the tissues due to its anti-oxidant activity (lowering lipid peroxidation, increasing glutathione levels, increasing glutathione reductase and catalase activity) (Sudheesh et al., 2009,2010; Ajith et al., 2014).

Clinical Findings:

Veterinary – ½ - 2 tsp/day

Ten post- chemotherapy canines were analyzed for fatigue. Urine was collected before and following 14 days of Poly MVA (human equivalent dose 2 tsp./day) and supplied to Genova Diagnostics for a Metabolic Analysis. Poly MVA increased Krebs Cycle markers indicating an enhanced Cellular Energy.

Human – 4 tsp/day

Multiple Sclerosis –associated fatigue:

Dr. Lauren Krupp, Stony Brook University (2014)

- Each patient took 4 teaspoons per day for 6 weeks. The patients were tested at their baseline visit and at the end of 6 weeks using three Multiple Sclerosis Fatigue Scales (Fatigue Severity Scale (FSS); PROMIS Fatigue; Multiple Sclerosis Fatigue Impact Scale (MSFIS)). There was a statistically significant decrease in each scale, leading the Principle Investigators to conclude that the product was “well tolerated and was associated with a clear reduction in fatigue severity and fatigue impact”.

Palliative Care Study: CIPLA pharmaceuticals (2010)

- Patients took Poly MVA for 24 days, followed by a 12 day clearance period. The following EORTC QLQ C30 parameters demonstrated statistically significant patient improvement: Cognitive Functioning, Emotional Functioning, Social Functioning, Fatigue, Sleep Disturbances, and Appetite Loss.

HIV-associated fatigue: Dr. Gary Blick, Circle Medical (2009)

- Statistically significant improvement in QOL/Energy/Fatigue: assessed using the Medical Outcomes Study (MOS) HIV QOL survey

Genova Diagnostics 1-800-522-4762 – to assess energy production or anti-oxidant activity
Metabolic Analysis – urine
Oxidative Stress – blood or urine

7 Shirley Street • Bohemia, NY 11716-1735 • Tel: (631) 589-0770 • Fax: (631) 589-0778